omega-n-methylarginine has been researched along with eptifibatide in 1 studies
| Studies (omega-n-methylarginine) | Trials (omega-n-methylarginine) | Recent Studies (post-2010) (omega-n-methylarginine) | Studies (eptifibatide) | Trials (eptifibatide) | Recent Studies (post-2010) (eptifibatide) |
|---|---|---|---|---|---|
| 4,411 | 344 | 336 | 907 | 220 | 212 |
| Protein | Taxonomy | omega-n-methylarginine (IC50) | eptifibatide (IC50) |
|---|---|---|---|
| Integrin beta-3 | Homo sapiens (human) | 0.226 | |
| Integrin alpha-IIb | Homo sapiens (human) | 0.226 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heitzer, T; Köke, K; Meinertz, T; Munzel, T; Ollmann, I | 1 |
1 trial(s) available for omega-n-methylarginine and eptifibatide
| Article | Year |
|---|---|
Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease.
Topics: Acetylcholine; Biological Availability; Blood Flow Velocity; Blood Platelets; Coronary Artery Disease; Endothelium, Vascular; Enzyme Inhibitors; Eptifibatide; Forearm; Humans; Male; Middle Aged; Nitric Oxide; Nitric Oxide Donors; omega-N-Methylarginine; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Plethysmography; Tirofiban; Tyrosine; Vasodilation; Vasodilator Agents; Vasomotor System | 2003 |